Related Experiment Videos
Resistance of tumor-derived DNA to restriction enzyme digestion
J L Parkes1, F C Hubbard, A Penn
1Institute of Environmental Medicine, New York University Medical Center, New York 10016.
Abstract:
The major finding of this work is that there are specific restriction enzyme inhibitors present in "purified" tumor DNA which cause partial digestion patterns when tumor DNA is digested by standard procedures with any of three commonly employed restriction enzymes (HindIII, KpnI, XbaI). These aberrant patterns are not seen when DNA of cell lines derived from these tumors is digested. Thus, when working with tumor DNA these restriction enzymes should be used with caution.
Insights
Tumor DNA contains inhibitors that cause partial digestion with common restriction enzymes like HindIII, KpnI, and XbaI. These aberrant patterns differ from cell line DNA, necessitating caution when analyzing tumor DNA.
Area of Science:
- Molecular Biology
- Genomics
- Cancer Research
Background:
- Restriction enzymes are crucial tools for DNA analysis.
- Standard DNA extraction and digestion protocols are widely used in research.
Purpose of the Study:
- To identify the cause of aberrant DNA digestion patterns observed in tumor DNA.
- To evaluate the reliability of standard restriction enzymes for tumor DNA analysis.
Main Methods:
- Digestion of purified tumor DNA and DNA from derived cell lines using restriction enzymes (HindIII, KpnI, XbaI).
- Analysis of DNA digestion patterns using standard gel electrophoresis techniques.
Main Results:
- Specific inhibitors in purified tumor DNA were found to cause partial digestion patterns.
- Aberrant digestion patterns were observed with HindIII, KpnI, and XbaI.
- These patterns were absent in DNA from tumor-derived cell lines.
Conclusions:
- Purified tumor DNA contains endogenous inhibitors affecting restriction enzyme activity.
- Standard restriction enzymes (HindIII, KpnI, XbaI) should be used with caution when analyzing tumor DNA.
- Results highlight potential pitfalls in molecular diagnostics and cancer research involving tumor DNA.